Lunai Bioworks Inc. 8-K

What Happened Lunai Bioworks, Inc. announced that on February 6, 2026 it received a Nasdaq notice that Nasdaq staff has determined to delist the Company’s securities from The Nasdaq Capital Market. Nasdaq found the Company was not in compliance with Listing Rule 5550(a)(2) after the bid price closed below $1.00 per share for 30 consecutive business days (December 23, 2025 through February 5, 2026). Because the Company effected a 1-for-10 reverse stock split on September 30, 2025, Nasdaq concluded the Company is ineligible for the usual 180-calendar-day cure period under Rule 5810(c)(3)(A)(iv). The Company filed a timely request for a hearing before the Nasdaq Hearings Panel (deadline noted as February 13, 2026); a timely hearing request stays any suspension of trading and the filing of a Form 25 pending the hearing outcome.

Key Details

• Nasdaq notice received: February 6, 2026; potential suspension at opening of business on February 18, 2026 if no timely appeal.
• Deficiency: closed bid price below $1.00 per share for 30 consecutive business days (Dec 23, 2025 – Feb 5, 2026); violates Nasdaq Rule 5550(a)(2).
• Reverse split: 1-for-10 reverse stock split effected September 30, 2025, which made the Company ineligible for the standard 180-day compliance period.
• Next procedural steps: Company requested a hearing (stays suspension and Form 25 filing); Nasdaq would file Form 25 to delist and deregister under Section 12(b) if the appeal is not pursued or not successful.

Why It Matters A Nasdaq delisting determination can materially affect shareholders: trading could be suspended and the Company’s securities could be removed from the Nasdaq Capital Market, reducing liquidity and potentially limiting investor access. Delisting may also lead to deregistration under Section 12(b), which can affect reporting and investor visibility. The Company has appealed and obtained a hearing stay for now, but there is no assurance the appeal will succeed. Investors should monitor further company disclosures about the hearing and any steps taken to regain compliance.